![Karin Nord](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Karin Nord
Fondateur chez Affibody Medical AB
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Carl Erik Mathias Uhlén | M | 70 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 26 ans |
Joachim Feldwisch | M | - |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Jose F. Suarez | M | 54 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
J. Kenneth Charles Knowles | M | 77 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Robert Forbes Burns | M | 77 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Stig Anders Lindberg | M | 52 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Anders Martin-Löf | M | 53 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 3 ans |
David Bejker | M | 49 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 6 ans |
Per Stefan Andersson-Engels | M | 64 |
Royal Institute of Technology
| 28 ans |
Camilla Soenderby | F | - |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Johannes Celander | M | - |
Royal Institute of Technology
| 5 ans |
Erik Walldén | M | 75 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | 2 ans |
Jan Ulf Sigvar J. Johansson | M | 79 |
Royal Institute of Technology
| 5 ans |
Marcus Lannerbro | M | 49 |
Royal Institute of Technology
| 1 ans |
Johan Pejnefors | M | - |
Royal Institute of Technology
| 2 ans |
Anders Mattias Letmark | M | 45 |
Royal Institute of Technology
| 5 ans |
Johan Conradsson | M | - |
Royal Institute of Technology
| 5 ans |
Mats Danielsson | M | 59 |
Royal Institute of Technology
| 3 ans |
Pontus Boman | M | 53 |
Royal Institute of Technology
| 4 ans |
Daniel Karlgren | M | - |
Royal Institute of Technology
| 1 ans |
Anton Lundqvist | M | 54 |
Royal Institute of Technology
| 3 ans |
Pasi Juhani Tolppanen | M | 57 |
Royal Institute of Technology
| 3 ans |
Peter Wall | M | 52 |
Royal Institute of Technology
| 4 ans |
Henrik Von Schoultz | M | - |
Royal Institute of Technology
| 12 ans |
Eva Nahari | F | - |
Royal Institute of Technology
| 5 ans |
Tuva Berg | F | - |
Royal Institute of Technology
| 12 ans |
Rickard Waldenlind | M | - |
Royal Institute of Technology
| 7 ans |
Carl-Johan Zetterberg Boudrie | M | 45 |
Royal Institute of Technology
| 5 ans |
Fredric Kastevik | M | 50 |
Royal Institute of Technology
| 1 ans |
Carl Henrik Gustaf Thane | M | - |
Royal Institute of Technology
| 3 ans |
Hans Lennart Rudolf Wigzell | M | 86 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Håkan Åström | M | 77 |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Per Ake Nygren | M | - |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Karin Hansson | M | 61 |
Royal Institute of Technology
| 3 ans |
Carl Jöran Fredrik Cassel | M | 51 |
Royal Institute of Technology
| 5 ans |
John Mikael Holtz Elvesjö | M | 47 |
Royal Institute of Technology
| 2 ans |
Anders Lundblad | M | - |
Royal Institute of Technology
| 3 ans |
Philip Axel Wilhelm Siberg | M | 51 |
Royal Institute of Technology
| 1 ans |
Mattias Feiff | M | 52 |
Royal Institute of Technology
| 4 ans |
Magnus Lagerström | M | 51 |
Royal Institute of Technology
| 4 ans |
Jan Peter Enoksson | M | 67 |
Royal Institute of Technology
| 3 ans |
Fredrik Frejd | M | - |
Affibody Medical AB
![]() Affibody Medical AB Pharmaceuticals: MajorHealth Technology Affibody Medical AB provides biopharmaceuticals services. It develops Affibody, an antibody mimetic and Albumod, a technology that enhances the efficacy of biopharmaceuticals by extending their circulatory half-life through a strong binding to albumin. The company was founded by Karin Nord and Carl Erik Mathias Uhlén in 1998 and is headquartered in Stockholm, Sweden. | - |
Fredrik Ramén | M | - |
Royal Institute of Technology
| 4 ans |
Hans Lundhagen | M | 52 |
Royal Institute of Technology
| 1 ans |
Daniel Wroblewski | M | - |
Royal Institute of Technology
| 4 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Suède | 45 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Karin Nord
- Réseau Personnel